Sylvia Hoang, MD
Family Medicine · Fremont, CANPI 1760549109
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $511 and has fallen 60.2% since, to $204 in 2025.
Across 63 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$163
- Johnson & Johnson$125
- Pfizer$122
- Boehringer Ingelheim$92
- Exact Sciences$81
- Lilly USA, LLC$77
- plus $539 from 19 others
What the payments were for
- Food & beverage$1,197100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $163 |
| Johnson & Johnson | 8 | $125 |
| Pfizer | 6 | $122 |
| Boehringer Ingelheim | 5 | $92 |
| Exact Sciences | 4 | $81 |
| Lilly USA, LLC | 3 | $77 |
| Akcea Therapeutics, Inc. | 1 | $55 |
| GSK | 2 | $51 |
| Novo Nordisk | 3 | $50 |
| Amgen | 2 | $40 |
| Impulse Dynamics (USA) Inc. | 1 | $35 |
| Neurocrine Biosciences, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $33 |
| Boston Scientific | 2 | $28 |
| Merck | 2 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| Abbott | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Edwards Lifesciences | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$1,197 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 227 | $316,297 |
| OzempicSemaglutide | 41 | $66,889 |
| EliquisApixaban | 38 | $56,935 |
| JanuviaSitagliptin Phosphate | 37 | $52,698 |
| XareltoRivaroxaban | 26 | $41,750 |
| FarxigaDapagliflozin Propanediol | 27 | $33,714 |
| LinzessLinaclotide | 25 | $30,609 |
| VemlidyTenofovir Alafenamide | 13 | $29,557 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $18,356 |
| Atorvastatin Calcium | 806 | $10,388 |
| Fluticasone Propionate HfaFluticasone Propionate | 19 | $9,892 |
| BreynaBudesonide/Formoterol Fumarate | 23 | $7,600 |
| Losartan Potassium | 687 | $7,100 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $6,086 |
| Arnuity ElliptaFluticasone Furoate | 11 | $5,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $92 | $316,297227 claims |
| Novo NordiskOzempic | $50 | $66,88941 claims |
| PfizerEliquis | $122 | $56,93538 claims |
| MerckJanuvia | $24 | $52,69837 claims |
| Johnson & JohnsonXarelto | $125 | $41,75026 claims |
| AstraZenecaFarxiga | $163 | $33,71427 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $51 | $23,39536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.
Other family medicine in Fremont
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.